Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bennett, M.
Right arrow Articles by Wee, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bennett, M.
Right arrow Articles by Wee, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care

Mike Bennett

St. Gemma's Hospice, Leeds

Viv Lucas

Mary Brennan

Garden House Hospice, Letchworth

Andrew Hughes

Valerie O'Donnell

Bee Wee

The management of ‘death rattle' was reviewed by a task group on behalf of the Association for Palliative Medicine's Science Committee. Evidence was searched for the effectiveness of various anti-muscarinic drugs in drying oropharyngeal and bronchial secretions in dying patients. Clinical guidelines were constructed based on evidence from volunteer and clinical studies. Death rattle occurs in half of all dying patients and some response occurs in around 80% of treated patients. Clinical studies demonstrate that subcutaneous hyoscine hydrobromide 400 mg is more effective at improving symptoms at 30 min than glycopyrronium 200 mg by the same route. Volunteer studies demonstrate that intramuscular glycopyrronium 400 mg is as effective in drying secretions at 30 min as a dose of 200 mg given intravenously. Duration of response is shortest for hyoscine butylbromide (1 h) and longest for glycopyrronium (more than 6 h). There is insufficient evidence to support the use of one drug over another in a continuous infusion and prescribers should base decisions on different characteristics of each anti-muscarinic drug.

Key Words: anti-muscarinic drugs • clinical guidelines • death rattle

Palliative Medicine, Vol. 16, No. 5, 369-374 (2002)
DOI: 10.1191/0269216302pm584oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
T. Morita, I. Hyodo, T. Yoshimi, M. Ikenaga, Y. Tamura, A. Yoshizawa, A. Shimada, T. Akechi, M. Miyashita, I. Adachi, et al.
Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies
Ann. Onc., April 1, 2005; 16(4): 640 - 647.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
E. Rees and J. Hardy
Novel consent process for research in dying patients unable to give consent
BMJ, July 24, 2003; 327(7408): 198.
[Abstract] [Full Text] [PDF]